In the last decade, important progress has been achieved in the prevention of chemotherapy-induced nausea and vomiting, in particular since the introduction of 5-HT3 antagonists which, when used in combination with steroids, can assure significant protection in the majority of patients. Nonetheless, for some relevant clinical problems there still is no satisfactory answer, and there are major differences in clinical practice regarding antiemetic use. This volume contains the results of the fifth Perugia International Cancer Conference which was organized in 8 sessions, a consensus document was prepared for each session forming a useful basis for future developments.
Sprache
Verlagsort
Verlagsgruppe
Illustrationen
3 s/w Abbildungen
XIII, 133 p. 3 illus.
Dateigröße
ISBN-13
978-3-642-72137-3 (9783642721373)
DOI
10.1007/978-3-642-72137-3
Schweitzer Klassifikation
Corticosteroids, Dopamine Antagonists, and Other Drugs.- Optimal Selection of Antiemetics in Children Receiving Cancer Chemotherapy.- Methodology of Antiemetic Trials: Response Assessment, Evaluation of New Agents, and Definition of Chemotherapy Emetogenicity.- Delayed Emesis Following Anticancer Chemotherapy.- Antiemetic Strategies for High-Dose Chemoradiotherapy-Induced Nausea and Vomiting.- Consensus Proposal for 5-HT3 Antagonists in the Prevention of Acute Emesis Related to Highly Emetogenic Chemotherapy.- Anticipatory Nausea and Vomiting in the Era of 5-HT3 Antiemetics.- Consensus Regarding Multiple-Day and Rescue Antiemetic Therapy.- Etiology and Prevention of Emesis Induced by Radiotherapy.- Statistical Considerations in the Design, Conduct, and Analysis of Antiemetic Clinical Trials.- Neuropharmacology of Emesis and Its Relevance to Antiemetic Therapy.
